Article Information
History
- May 31, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Anna Luiza Silva Almeida Vicente1,2,*,
- Alexei Novoloaca2,
- Vincent Cahais2,
- Zainab Awada2,
- Cyrille Cuenin2,
- Natália Spitz2,
- André Lopes Carvalho1,
- Adriane Feijó Evangelista1,
- Camila Souza Crovador1,
- Rui Manuel Reis1,3,4,
- Zdenko Herceg2,†,
- Vinicius de Lima Vazquez1,5,† and
- Akram Ghantous2,†,*
- 1Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
- 2International Agency for Research on Cancer (IARC), Lyon, France
- 3Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, Portugal
- 4ICVS/3B’s-PT Government Associate Laboratory, Braga/Guimarães, Portugal
- 5Department of Surgery – Melanoma and Sarcoma, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
- ↵*Correspondence to Akram Ghantous, PhD, Epigenomics and Mechanisms Branch, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69008 Lyon, France, E-mail: GhantousA{at}iarc.fr, Anna Luiza Vicente, Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, 14784-400, Barretos, Brazil, E-mail: annaluizaalmeida{at}hotmail.com
↵† These authors jointly supervised this work
Posted May 31, 2022.
Cutaneous and acral melanoma cross-OMICs reveals prognostic cancer drivers associated with pathobiology and ultraviolet exposure
